• Hologic Inc.

    Hologic is a leading medical technology company including ThinPrep® and Panther® dedicated to improving women’s health and well-being through early detection and treatment. One of their focus is in vitro diagnostics solutions.

    ThinPrep® Pap test is the first liquid-based cytology option in cervical disease screening since 1996.It has been the most widely used Pap test in the world, with hundreds of published, peer-reviewed studies demonstrating significant benefits as compared to conventional pap smear test. Thinprep is also the only FDA-approved test for both Pap and HPV testing from one vial to screen for cervical cancer and other ancillary tests.

    The Panther® system is a fully automated testing platform with true sample-to-result automation (at random-access loading), adaptable workflow options, a consolidated testing menu and proven assay chemistry. The system allows labs to take control of productivity with several intuitive features.



  • Taigen

    Fully automate DNA/RNA extraction from raw samples to nucleic acid elution.

    Suitable for laboratories to perform clinical, agricultural, forensic, research and applied.



  • Texas Biogene

    Dedicated to development of nucleic acid testing kits. Quality HLA Typing kits for immune matching of bone marrow, cord blood and solid organ transplants.



  • Seegene, Inc.

    Global leader of multiplex molecular diagnostics with core technologies TOCE™,

    READ™, DPO™ and ACP™ that overcomes conventional PCR.

    Seegene’s simultaneous and multiple detection technologies, which are unique and superior, have already surpassed the limits of conventional diagnostic techniques and provided a means of testing dozens of pathogens at once. These technologies result in cost reduction for patients because it allows detection of multiple pathogens in a single test and definitely can provide benefits of more personalised diagnostic opportunities. For doctors, these technologies provide opportunities for more accurate and efficient treatment.



  • Biocartis NV

    An innovative commercial stage molecular diagnostics (MDx) company that provides next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Their proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

    Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases.